| 2025年中报 | 2024年年报 | 2023年年报 | |
|---|---|---|---|
| 营业收入(元) | |||
| 仿制药(元) | 36,628,844.20 | 55,520,356.11 | 20,550,654.86 |
| 医药技术服务(元) | 2,028,531.82 | 5,293,266.95 | 6,120,655.16 |
| 中间体及原料药(元) | 37,508,175.27 | 114,080,151.26 | 98,093,642.39 |
| 营业成本(元) | |||
| 仿制药(元) | 29,173,919.87 | 40,573,901.82 | 13,963,709.31 |
| 医药技术服务(元) | 653,704.36 | 4,432,162.16 | 2,740,594.24 |
| 中间体及原料药(元) | 36,369,442.18 | 82,247,367.68 | 75,730,786.02 |
| 毛利(元) | |||
| 仿制药(元) | 7,454,924.33 | 14,946,454.29 | 6,586,945.55 |
| 医药技术服务(元) | 1,374,827.46 | 861,104.79 | 3,380,060.92 |
| 中间体及原料药(元) | 1,138,733.09 | 31,832,783.58 | 22,362,856.37 |
| 毛利率(%) | |||
| 仿制药(%) | 20.35 | 26.92 | 32.05 |
| 医药技术服务(%) | 67.77 | 16.27 | 55.22 |
| 中间体及原料药(%) | 3.04 | 27.90 | 22.80 |
| 收入构成(%) | |||
| 仿制药(%) | 48.09 | 31.75 | 16.47 |
| 医药技术服务(%) | 2.66 | 3.03 | 4.91 |
| 中间体及原料药(%) | 49.25 | 65.23 | 78.62 |
| 毛利构成(%) | |||
| 仿制药(%) | 74.78 | 31.37 | 20.37 |
| 医药技术服务(%) | 13.79 | 1.81 | 10.45 |
| 中间体及原料药(%) | 11.42 | 66.82 | 69.17 |